Insmed reported $247.26M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Cytokinetics USD 104.9M 13.17M Mar/2026
DBV Technologies USD 13.4M 8.14M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 247.26M 34.78M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026